NCT00369174View on ClinicalTrials.gov

Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

August 31, 2007

Conditions
Oral Leukoplakia
Interventions
DRUG

rosiglitazone maleate

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00369174 - Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia | Biotech Hunter | Biotech Hunter